<DOC>
	<DOCNO>NCT01896193</DOCNO>
	<brief_summary>This study evaluate antiviral efficacy , safety , tolerability sofosbuvir plus ribavirin administer 16 week 24 week participant chronic genotype 1 ( GT1 ) genotype 3 ( GT3 ) hepatitis C virus ( HCV ) infection .</brief_summary>
	<brief_title>Safety Efficacy Study Sofosbuvir Plus Ribavirin Treatment-Naive Adults With Genotype 1 3 Chronic HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Confirmed chronic genotype 1 3 HCV infection HCV treatmentnaive Individuals cirrhosis status assessment ; liver biopsy may require . Screening laboratory value within predefined threshold Use two effective contraception method female childbearing potential sexually active male Pregnant nursing female male pregnant female partner Infection hepatitis B virus ( HBV ) human immunodeficiency virus ( HIV ) Contraindication ribavirin therapy Excessive alcohol ingestion define protocol History solid organ transplantation Current prior history clinical hepatic decompensation History clinically significant illness medical disorder may interfere individual 's treatment , assessment , compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>